PMN
ProMIS Neurosciences Inc.
9.40$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +290.7% | -15.9% | +124.3% | +36.6% | -30.1% | -33.2% | +1,520.5% | -43.9% | +8.1% | +38.9% | -51.4% | |
| – | +421.3% | -16.4% | +134.8% | +38.1% | -30.4% | -38.7% | +1,705.6% | -43.9% | +8.4% | +38.9% | -51.4% | |
| – | +3,511.7% | -21.2% | +137.3% | +41.4% | -30.5% | -38.1% | +1,982.3% | -50.1% | +17.9% | +5.5% | -54.0% | |
| – | +3,675.6% | -20.2% | +82.8% | +76.6% | -29.9% | -35.1% | +1,842.4% | -49.9% | +17.3% | +5.5% | -53.8% | |
| – | +1,317.5% | -24.4% | -68.7% | -46.4% | +116.0% | -69.9% | +6,333.9% | +47.1% | +9.8% | -0.8% | -53.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -94.1% | -94.6% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -8.2% | -8.9% | -9.8% | -10.8% | -12.1% | -13.8% | -16.1% | +8.6% | – | – | – | |
| – | +11.8% | +63.1% | -29.0% | +183.9% | -7.4% | +43.3% | +536.6% | -1.5% | -34.4% | -75.4% | +330.9% | |
| – | +11.8% | +63.1% | -29.0% | +183.9% | -7.4% | +43.3% | -51.1% | +893.1% | -19.9% | -76.3% | +369.3% | |
| – | – | +2.2% | – | – | – | – | – | – | – | – | – | |
| – | -15.7% | +54.7% | -59.4% | +173.0% | -34.7% | +20.0% | -7.3% | +946.6% | +44.9% | -77.8% | +46.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -88.4% | +2,108.4% | -24.6% | -65.6% | -355.2% | – | -134.3% | – | +339.3% | -107.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +78.0% | +57.3% | +21.1% | +16.2% | +8.6% | +9.9% | +21.5% | +29.7% | +63.8% | +115.3% | +66.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.